134 related articles for article (PubMed ID: 37059106)
1. An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma.
Chen YX; Wang ZX; Jin Y; Zhao Q; Liu ZX; Zuo ZX; Ju HQ; Cui C; Yao J; Zhang Y; Li M; Feng J; Tian L; Xia XJ; Feng H; Yao S; Wang FH; Li YH; Wang F; Xu RH
Cancer Cell; 2023 May; 41(5):919-932.e5. PubMed ID: 37059106
[TBL] [Abstract][Full Text] [Related]
2. Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping.
Jesinghaus M; Steiger K; Slotta-Huspenina J; Drecoll E; Pfarr N; Meyer P; Konukiewitz B; Bettstetter M; Wieczorek K; Ott K; Feith M; Langer R; Weichert W; Specht K; Boxberg M
Oncotarget; 2017 Jul; 8(29):46756-46768. PubMed ID: 28657901
[TBL] [Abstract][Full Text] [Related]
3. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial.
Zhang G; Yuan J; Pan C; Xu Q; Cui X; Zhang J; Liu M; Song Z; Wu L; Wu D; Luo H; Hu Y; Jiao S; Yang B
EBioMedicine; 2023 Apr; 90():104515. PubMed ID: 36921563
[TBL] [Abstract][Full Text] [Related]
4. First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50).
Kato K; Doki Y; Ogata T; Motoyama S; Kawakami H; Ueno M; Kojima T; Shirakawa Y; Okada M; Ishihara R; Kubota Y; Amaya-Chanaga C; Chen T; Matsumura Y; Kitagawa Y
Esophagus; 2023 Apr; 20(2):291-301. PubMed ID: 36401133
[TBL] [Abstract][Full Text] [Related]
5. Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis.
Wu HX; Pan YQ; He Y; Wang ZX; Guan WL; Chen YX; Yao YC; Shao NY; Xu RH; Wang F
J Clin Oncol; 2023 Mar; 41(9):1735-1746. PubMed ID: 36473145
[TBL] [Abstract][Full Text] [Related]
6. Deleterious alterations of DNA damage response and repair genes and clinical benefit to anti-PD-1 therapy in esophageal squamous cell carcinoma.
Guo JC; Lin CC; Hsu CL; Huang TC; Kuo HY; Lin CY; Lien MY; Cheng AL; Hsu CH
Esophagus; 2022 Oct; 19(4):693-701. PubMed ID: 35816242
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
8. Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma.
Lee HK; Kwon MJ; Ra YJ; Lee HS; Kim HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Min KW; Kang SY
Diagn Pathol; 2020 Oct; 15(1):126. PubMed ID: 33054840
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.
Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J
Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China.
Liu S; Jiang N; Dou L; Li S
Front Immunol; 2023; 14():1172242. PubMed ID: 37215110
[TBL] [Abstract][Full Text] [Related]
11. Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials.
Lu Y; Wang W; Wang F
Front Immunol; 2023; 14():1171671. PubMed ID: 37205107
[TBL] [Abstract][Full Text] [Related]
12. PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis.
Zhu X; Shanzhou Q; Li D; Pang X; Ma D
BMC Cancer; 2021 Nov; 21(1):1195. PubMed ID: 34758782
[TBL] [Abstract][Full Text] [Related]
13. Programmed cell death-ligand 1 expression predicts poor treatment response and prognostic value in esophageal squamous cell carcinoma patients without esophagectomy.
Zhang F; Zhu X; Zhang Q; Zhou P; Hao L
Aging (Albany NY); 2021 Jul; 13(14):18827-18838. PubMed ID: 34297698
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers predicting the response to chemotherapy and the prognosis in patients with esophageal squamous cell carcinoma.
Inoue S; Yoshida T; Nishino T; Goto M; Aoyama M; Kawakita N; Yamamoto Y; Yoshihito F; Takizawa H; Tangoku A
Gen Thorac Cardiovasc Surg; 2021 Mar; 69(3):525-533. PubMed ID: 33449265
[TBL] [Abstract][Full Text] [Related]
15. Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma.
Mitani S; Kawakami H; Shiraishi O; Kanemura H; Suzuki S; Haratani K; Hayashi H; Yonesaka K; Chiba Y; Yasuda T; Nakagawa K
Esophagus; 2023 Apr; 20(2):281-289. PubMed ID: 36484900
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Chemotherapy Increases PD-L1 Expression and CD8
Fukuoka E; Yamashita K; Tanaka T; Sawada R; Sugita Y; Arimoto A; Fujita M; Takiguchi G; Matsuda T; Oshikiri T; Nakamura T; Suzuki S; Kakeji Y
Anticancer Res; 2019 Aug; 39(8):4539-4548. PubMed ID: 31366557
[TBL] [Abstract][Full Text] [Related]
17. Prognostic biomarker study in patients with clinical stage I esophageal squamous cell carcinoma: JCOG0502-A1.
Oshima K; Kato K; Ito Y; Daiko H; Nozaki I; Nakagawa S; Shibuya Y; Kojima T; Toh Y; Okada M; Hironaka S; Akiyama Y; Komatsu Y; Maejima K; Nakagawa H; Onuki R; Nagai M; Kato M; Kanato K; Kuchiba A; Nakamura K; Kitagawa Y
Cancer Sci; 2022 Mar; 113(3):1018-1027. PubMed ID: 34962019
[TBL] [Abstract][Full Text] [Related]
18. Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade.
Yan C; Ma X; Guo Z; Wei X; Han D; Zhang T; Chen X; Cao F; Dong J; Zhao G; Gao X; Wang T; Jiang Y; Wang P; Pang Q; Zhang W
Oncoimmunology; 2022; 11(1):2025668. PubMed ID: 35036077
[TBL] [Abstract][Full Text] [Related]
19. Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma.
Yan T; Cui H; Zhou Y; Yang B; Kong P; Zhang Y; Liu Y; Wang B; Cheng Y; Li J; Guo S; Xu E; Liu H; Cheng C; Zhang L; Chen L; Zhuang X; Qian Y; Yang J; Ma Y; Li H; Wang F; Liu J; Liu X; Su D; Wang Y; Sun R; Guo S; Li Y; Cheng X; Liu Z; Zhan Q; Cui Y
Nat Commun; 2019 Apr; 10(1):1670. PubMed ID: 30975989
[TBL] [Abstract][Full Text] [Related]
20. Immuno-genomic profiling of biopsy specimens predicts neoadjuvant chemotherapy response in esophageal squamous cell carcinoma.
Sasagawa S; Kato H; Nagaoka K; Sun C; Imano M; Sato T; Johnson TA; Fujita M; Maejima K; Okawa Y; Kakimi K; Yasuda T; Nakagawa H
Cell Rep Med; 2022 Aug; 3(8):100705. PubMed ID: 35944530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
